Nexilico, Inc.

Nexilico, Inc.Nexilico, Inc.Nexilico, Inc.

Nexilico, Inc.

Nexilico, Inc.Nexilico, Inc.Nexilico, Inc.
  • Home
  • About Us
  • News
  • Contact Us
  • More
    • Home
    • About Us
    • News
    • Contact Us
  • Home
  • About Us
  • News
  • Contact Us

News

Nexilico joins Google for Startups Cloud Program at the Scale Tier for AI-first startups

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico gains access to up to $350,000 in Google Cloud credits, expert mentorship, exclusive technical resources, go-to-market guidance, and direct integration with Google Cloud’s AI/ML ecosystem.

Learn more

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics have entered into a collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics.

Learn more

Nexilico joins NVIDIA Inception Program to accelerate AI-powered microbiome engineering

Nexilico and Siolta Therapeutics enter collaboration agreement on Necrotizing Enterocolitis

Nexilico joins NVIDIA Inception Program to accelerate AI-powered microbiome engineering

Nexilico joins an elite group of startups leveraging AI to solve some of the world's most challenging problems, underscoring Nexilico's mission to harness the power of the microbiome for improving human health.

Learn more

Nexilico secures NIH funding to pioneer microbiome solutions for xenobiotic toxicity

Nexilico secures NIH funding to pioneer microbiome solutions for xenobiotic toxicity

Nexilico joins NVIDIA Inception Program to accelerate AI-powered microbiome engineering

Nexilico has been awarded a grant from the National Institues of Health (NIH) to develop a novel microbiome-based solution to protect human health from the harmful effects of xenobiotic compounds.

Learn more

Nexilico Awarded $1M to advance precision microbiome engineering

Nexilico secures NIH funding to pioneer microbiome solutions for xenobiotic toxicity

Nexilico Awarded $1M to advance precision microbiome engineering

Nexilico has been awarded $1M in funding from the NSF to develop an AI-driven  discovery platform for development of microbiome therapeutics for a

variety of indications. 

Learn more

Wyatt Hartman joins Nexilico as the Director of R&D

Nexilico secures NIH funding to pioneer microbiome solutions for xenobiotic toxicity

Nexilico Awarded $1M to advance precision microbiome engineering

Wyatt is an established computational biologist with more than 15 years of experience in development of a variety of microbiome technologies in multiple academic and industrial positions.

Learn more

Nexilico Awarded NIH Funding to Predict Gut Microbiome Effect on Drug Efficacy and Toxicity

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico Awarded NIH Funding to Predict Gut Microbiome Effect on Drug Efficacy and Toxicity

  Nexilico and collaborators are awarded a grant to develop a new computational solution for reliable and cost-effective prediction of gut microbiome-mediated drug metabolism and its effect on drug efficacy and toxicity.  

Learn more

Nexilico and Microvi Biotech Inc. Awarded $1.12M by the National Institutes of Health

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico Awarded NIH Funding to Predict Gut Microbiome Effect on Drug Efficacy and Toxicity

Nexilico's collaboration with Microvi Biotech Inc. on developing precision biological processes receives a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for $1.12M.

Learn more

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico, Inc. is selected by the National Institutes of Health, as one of the NIH SBIR awardees to exhibit  their technology at the upcoming Biotechnology Innovation Organization (BIO) International Convention.

Learn more

Nexilico Awarded Competitive Grant from the National Science Foundation

The National Institutes of Health Awards Nexilico with Phase I SBIR Grant

Nexilico Selected as one of the 30 NIH SBIR awardees to attend the BIO International Convention

Nexilico, Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct R&D work on the personalization of gut microbiome therapeutics.

Learn more

The National Institutes of Health Awards Nexilico with Phase I SBIR Grant

The National Institutes of Health Awards Nexilico with Phase I SBIR Grant

The National Institutes of Health Awards Nexilico with Phase I SBIR Grant

Nexilico was selected to receive a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for $225,000 to develop a predictive  platform for gut microbiome precision medicine. 

Learn more

Copyright © 2025 Nexilico, Inc. - All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept